First Time Loading...
S

Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336

Watchlist Manager
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336
Watchlist
Price: 23.96 CNY 1.91% Market Closed
Updated: May 2, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Sunshine Guojian Pharmaceutical Shanghai Co Ltd

Wall Street analysts forecast Sunshine Guojian Pharmaceutical Shanghai Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Sunshine Guojian Pharmaceutical Shanghai Co Ltd is 33.08 CNY with a low forecast of 32.75 CNY and a high forecast of 34.05 CNY.

Lowest Forecast
Wall Street Target
32.75 CNY
37% Upside
Average Forecast
Wall Street Target
33.08 CNY
38% Upside
Highest Forecast
Wall Street Target
34.05 CNY
42% Upside
Lowest
Price Target
32.75 CNY
37% Upside
Average
Price Target
33.08 CNY
38% Upside
Highest
Price Target
34.05 CNY
42% Upside
Sunshine Guojian Pharmaceutical Shanghai Co Ltd Competitors:
Price Targets
4978
ReproCell Inc
94% Upside
IONS
Ionis Pharmaceuticals Inc
31% Upside
9966
Alphamab Oncology
94% Upside
6855
Ascentage Pharma Group International
74% Upside
4978
ReproCell Inc
94% Upside
IONS
Ionis Pharmaceuticals Inc
31% Upside
9966
Alphamab Oncology
94% Upside
6855
Ascentage Pharma Group International
74% Upside
BMRN
Biomarin Pharmaceutical Inc
36% Upside
I
TIL
Instil Bio Inc
163% Upside
TGTX
TG Therapeutics Inc
94% Upside
KMDA
Kamada Ltd
128% Upside

Revenue
Forecast

Revenue Estimate
Sunshine Guojian Pharmaceutical Shanghai Co Ltd

For the last 4 years the compound annual growth rate for Sunshine Guojian Pharmaceutical Shanghai Co Ltd's revenue is -8%. The projected CAGR for the next 4 years is 16%.

-8%
Past Growth
16%
Estimated Growth
Estimates Accuracy
-20%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Sunshine Guojian Pharmaceutical Shanghai Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Sunshine Guojian Pharmaceutical Shanghai Co Ltd

For the last 4 years the compound annual growth rate for Sunshine Guojian Pharmaceutical Shanghai Co Ltd's net income is -40%. The projected CAGR for the next 4 years is 54%.

-40%
Past Growth
54%
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's stock price target?
Price Target
33.08 CNY

According to Wall Street analysts, the average 1-year price target for Sunshine Guojian Pharmaceutical Shanghai Co Ltd is 33.08 CNY with a low forecast of 32.75 CNY and a high forecast of 34.05 CNY.

What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Revenue forecast?
Projected CAGR
16%

For the last 4 years the compound annual growth rate for Sunshine Guojian Pharmaceutical Shanghai Co Ltd's revenue is -8%. The projected CAGR for the next 4 years is 16%.

What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Net Income forecast?
Projected CAGR
54%

For the last 4 years the compound annual growth rate for Sunshine Guojian Pharmaceutical Shanghai Co Ltd's net income is -40%. The projected CAGR for the next 4 years is 54%.

ALPHA SPREAD
Join more than 133,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.